First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.

Por Athanassiou, A. E., Bafaloukos, D., Pectasides, D., Dimitriadis, M., Varthalitis, I., Barbounis, V.
Publicado em 1989

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.

Por Pectasides, D., Yianniotis, H., Alevizakos, N., Bafaloukos, D., Barbounis, V., Varthalitis, J., Dimitriadis, M., Athanassiou, A.
Publicado em 1989

Antibody-guided irradiation of malignant pleural and pericardial effusions.

Por Pectasides, D., Stewart, S., Courtenay-Luck, N., Rampling, R., Munro, A. J., Krausz, T., Dhokia, B., Snook, D., Hooker, G., Durbin, H.
Publicado em 1986

A low pH enzyme linked immunoassay using two monoclonal antibodies for the serological detection and monitoring of breast cancer.

Por Dhokia, B., Pectasides, D., Self, C., Habib, N. A., Hershman, M., Wood, C. B., Munro, A. J., Epenetos, A. A.
Publicado em 1986

A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.

Por Dhokia, B., Canney, P. A., Pectasides, D., Munro, A. J., Moore, M., Wilkinson, P. M., Self, C., Epenetos, A. A.
Publicado em 1986

Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon

Por Gogas, H, Kefala, G, Bafaloukos, D, Frangia, K, Polyzos, A, Pectasides, D, Tsoutsos, D, Panagiotou, P, Ioannovich, J, Loukopoulos, D
Publicado em 2002

Immunoscintigraphy with 131I-labelled H17E2 monoclonal antibody compared with conventional lymphangiography and computed tomography in the detection of metastases in patients with...

Por Pectasides, D., Vonorta, P., Tsialta-Salihou, A., Pateniotis, K., Barbounis, V., Kayianni, H., Arapantoni, P., Taylor-Papadimitriou, J., Epenetos, A., Koutsiouba, P.
Publicado em 1990

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer

Por Ihnen, M, Wirtz, R M, Kalogeras, K T, Milde-Langosch, K, Schmidt, M, Witzel, I, Eleftheraki, A G, Papadimitriou, C, Jänicke, F, Briassoulis, E, Pectasides, D, Rody, A, Fountzilas, G, Müller, V
Publicado em 2010

Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

Por Koutras, A K, Kalogeras, K T, Dimopoulos, M-A, Wirtz, R M, Dafni, U, Briasoulis, E, Pectasides, D, Gogas, H, Christodoulou, C, Aravantinos, G, Zografos, G, Timotheadou, E, Papakostas, P, Linardou, H, Razis, E, Economopoulos, T, Kalofonos, H P, Fountzilas, G
Publicado em 2008